The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors

What is it about?

Pulmonary Fibrosis (PF), a pathological outcome of chronic and acute interstitial lung diseases, is a key component of the “post-acute COVID-19 syndrome” that may severely complicate patients’ clinical course. Our study highlights the importance of both patient-related and disease-related contributing risk factors for PF in COVID-19 survivors and makes it definitely clear the possible use of laboratory biomarkers for identifying the patients at greatest risk of developing this disease.

Featured Image